Platform
How the RNA QR code compresses a transcriptome into two scores, and why the method is compound-agnostic.
Investors
Materials on request
Bioceuticals.AI shares its investor materials privately, on request, with accredited investors. Nothing on this public site is an offer to sell or a solicitation of an offer to buy any security.
Request access
Email [email protected] with your name, firm and accreditation status. We reply with the current deck and a data-room link.
What you will receive
The deck and the evidence behind it
Evidence
The retrospective breast and prostate analyses on public data, with full statistics and the held-out design. RETROSPECTIVE · PUBLIC DATA (GEO/TCGA) · PRELIMINARY
EBV program
The three pre-registered analyses, their success criteria and the stage plan.
Any offering is made only to qualified persons through definitive documents. Research-stage; not reviewed by the FDA.
Market context
A large, inefficient market
Figures below are market context, not a projection of Bioceuticals.AI revenue, and nothing here is an offer to sell or a solicitation to buy any security.
$50B+
Global clinical-trial services market.
$20B+
Estimated annual waste from failed late-stage oncology trials.
$15B+
Companion-diagnostics market, growing at roughly 12% CAGR.
Immediate beachhead
Phase II/III oncology trials, where patient selection alone can materially change trial economics. CROs seeking differentiated, biomarker-driven enrichment services. Pharma R&D seeking faster go/no-go decisions.
Expansion markets
Drug-repurposing platforms, autoimmune and CNS disorders, precision vaccinology, and EEG QR codes for neuropsychiatric biomarkers.
Positioning
Why RNA QR codes
Existing alternatives (WGCNA, Oncotype DX, FoundationOne) either lack a unifying visual code, do not provide a drug-response index, or focus on single pathways. The RNA QR code integrates discovery, stratification and monitoring into one system.
Systems-level, not single-gene
Captures network-wide co-expression across 80+ metabolon modules rather than any individual mutation or protein biomarker.
Quantitative, comparable metrics
TI and RI convert qualitative differences into objective numbers; drugs ranked head-to-head, patients scored on one framework.
Cross-disease platform
Early evidence in breast and prostate cancer; the patent covers additional cancer types, autoimmune and CNS indications, and non-genomic modalities (EEG, proteomics).
First-mover IP
Provisional patent (Jan 2026) covering the PRCA method, RQC generation, TI/RI metrics, trial enrichment, companion Dx and EEG QR codes; 9 claims.
Market figures are drawn from public third-party estimates and are provided for context only. Research-stage; not reviewed by the FDA.